Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Carmen Garnacho"'
Autor:
Daniel J. García-Domínguez, Soledad López-Enríquez, Gonzalo Alba, Carmen Garnacho, Carlos Jiménez-Cortegana, Rocío Flores-Campos, Luis de la Cruz-Merino, Nabil Hajji, Víctor Sánchez-Margalet, Lourdes Hontecillas-Prieto
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 2, p 1195 (2024)
Cancer is a complex disease that, despite advances in treatment and the greater understanding of the tumor biology until today, continues to be a prevalent and lethal disease. Chemotherapy, radiotherapy, and surgery are the conventional treatments, w
Externí odkaz:
https://doaj.org/article/61ae30b5083743feb8847aabd49c9e8a
Autor:
María Luisa Sánchez-León, Carlos Jiménez-Cortegana, Silvia Silva Romeiro, Carmen Garnacho, Luis de la Cruz-Merino, Daniel J. García-Domínguez, Lourdes Hontecillas-Prieto, Víctor Sánchez-Margalet
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 6, p 5208 (2023)
Breast cancer (BC) continues to be the most diagnosed tumor in women and a very heterogeneous disease both inter- and intratumoral, mainly given by the variety of molecular profiles with different biological and clinical characteristics. Despite the
Externí odkaz:
https://doaj.org/article/7c2727b3b53646c8ba4b3b313ef25146
Autor:
Carmen Garnacho, Silvia Muro
Publikováno v:
Journal of Drug Targeting. 25:786-795
Enzyme replacement is a viable treatment for diseases caused by genetic deficiency of lysosomal enzymes. However, suboptimal access of enzymes to target sites limits this strategy. Polymer nanocarriers (NCs) coated with antibody against intercellular
Autor:
Carmen Garnacho
Publikováno v:
Scopus-Elsevier
Over the last half century, the delivery of pharmacologically active substances, such as synthetic drugs, natural compounds, gene material and many other pharmaceutical products, has been widely studied. Understanding the interactions of drug carrier
A Comparative Study on the Alterations of Endocytic Pathways in Multiple Lysosomal Storage Disorders
Publikováno v:
Molecular Pharmaceutics. 13:357-368
Many cellular activities and pharmaceutical interventions involve endocytosis and delivery to lysosomes for processing. Hence, lysosomal processing defects can cause cell and tissue damage, as in lysosomal storage diseases (LSDs) characterized by lys
Publikováno v:
Molecular Pharmaceutics. 12:1366-1376
Pharmaceutical intervention often requires therapeutics and/or their carriers to enter cells via endocytosis. Therefore, endocytic aberrancies resulting from disease represent a key, yet often overlooked, parameter in designing therapeutic strategies
Publikováno v:
Molecular Pharmaceutics
Drugs often use endocytosis to achieve intracellular delivery, either by passive uptake from the extracellular fluid or by active targeting of cell surface features such as endocytic receptors. An example is enzyme replacement therapy, a clinically p
Publikováno v:
Molecular therapy : the journal of the American Society of Gene Therapy. 25(7)
Acid sphingomyelinase deficiency in type B Niemann-Pick disease leads to lysosomal sphingomyelin storage, principally affecting lungs, liver, and spleen. Infused recombinant enzyme is beneficial, yet its delivery to the lungs is limited and requires
Publikováno v:
Biomaterials. 34:3459-3466
Modification of drug delivery nanomaterials with affinity molecules that facilitate targeting, has rendered a new class of ligands for cell receptors, which often possess valency and dimensions different from natural counterparts. Designing strategie
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 32:1178-1185
Objective— Engagement of intercellular adhesion molecule 1 (ICAM-1) on endothelial cells by ICAM-1-targeted carriers induces cell adhesion molecule–mediated endocytosis, providing intraendothelial delivery of therapeutics. This pathway differs fr